Abstract | Degeneration of the intervertebral discs (IVDs) is a major contributor to back, neck and radicular pain. IVD degeneration is characterized by increases in levels of the proinflammatory cytokines TNF, IL-1α, IL-1β, IL-6 and IL-17 secreted by the IVD cells; these cytokines promote extracellular matrix degradation, chemokine production and changes in IVD cell phenotype. The resulting imbalance in catabolic and anabolic responses leads to the degeneration of IVD tissues, as well as disc herniation and radicular pain. The release of chemokines from degenerating discs promotes the infiltration and activation of immune cells, further amplifying the inflammatory cascade. Leukocyte migration into the IVD is accompanied by the appearance of microvasculature tissue and nerve fibres. Furthermore, neurogenic factors, generated by both disc and immune cells, induce expression of pain-associated cation channels in the dorsal root ganglion. Depolarization of these ion channels is likely to promote discogenic and radicular pain, and reinforce the cytokine-mediated degenerative cascade. Taken together, an enhanced understanding of the contribution of cytokines and immune cells to these catabolic, angiogenic and nociceptive processes could provide new targets for the treatment of symptomatic disc disease. In this Review, the role of key inflammatory cytokines during each of the individual phases of degenerative disc disease, as well as the outcomes of major clinical studies aimed at blocking cytokine function, are discussed.
Introduction
Low back pain is a highly prevalent condition; estimates suggest that as many as 84% of individuals in the general population suffer from low back pain at some point in their lifetime, 1 and many are chronically disabled as a result of this condition. Approximately 25% of the US population is estimated to be suffering from low back and neck pain. 2 Likewise, the lifetime incidence of neck pain has been reported to be greater than 65%, with up to 54% of the population experiencing neck pain within the last 6 months in this study. 3 The socio-economic costs associated with these conditions are enormous. Indeed, they are estimated to have been $85 billion in 2008 in the USA (slightly more than the combined gross domestic pro ducts of Malta, Jordan, Fiji, Bhutan and Bolivia) 2 and in the UK, in terms of lost productivity, disability benefits total more than £12 billion. 4 As such, low back pain is one of the most prevalent musculoskeletal conditions affecting Western society, and represents a huge drain on medical resources worldwide. 2, 4, 5 A widely recognized contributor to back pain is degeneration of the intervertebral disc (IVD), the soft tissue between the vertebrae that absorbs and distributes applied loads and lends flexibility to the spine. 6, 7 Indeed, for the past 200 years, low back pain has been associated with IVD degeneration and, by inference, linked to ageing, excessive manual labour and, more recently, to genetic factors. As degeneration proceeds, elevated levels of inflammatory cytokines, increased aggrecan and collagen degradation, and changes in IVD cell phenotypes occur within the discal tissue. 8 The subsequent loss of hydrophilic extracellular matrix (ECM) molecules leads to structural changes and spinal instability, and is the main cause of disc herniation, sciatica and possibly spinal steno sis. 8 However, although a majority of adults over the age of 30 years have some form of structural degeneration of one or more IVDs, this process is not always accompanied by pain and might be a manifestation of the ageing process. 9, 10 Therefore, an event secondary to a structural deficit, such as injury or leakage of nucleus pulposus (NP; the gelatinous core of the disc) material through annular fissures, is likely to result in recruitment of immune cells to the disc, which then triggers pain generation. From this perspective, in the following discussion, the term IVD degeneration is used in the context of symptomatic (painful) disease.
Herein, we provide a general introduction to the pathogenesis of IVD degeneration and the relationship between IVD degenerative processes and low back pain. However, we focus our discussion on the role of inflammatory cytokines secreted by the disc cells resident within the NP and annulus fibrosus (AF; the fibro cartilagenous tissue that contains the NP) and by invading immune cells, which are central to the pathogenesis of IVD disease. abnormal production of cytokines and catabolic molecules by IVD cells. [8] [9] [10] [11] [12] [13] [14] These factors include genetic predisposition, smoking, infection, abnormal biomechanical loading, decreased nutrient transport across the vertebral endplates that contact the disc, and ageing. [8] [9] [10] [11] [12] [13] [14] The relative importance of each of these factors in IVD degeneration is currently unknown, although they are all associated with a common disease phenotype: loss of water signal detected by T2-weighted MRI, referred to as a 'black disc' , together with some degree of inflammation and bulging or herniation of the NP (Figure 1) .
Regardless of the initiating factor, IVD degeneration is thought to be mediated by the abnormal production of proinflammatory molecules secreted by both NP cells and AF cells, as well as macrophages, T cells and neutrophils. [15] [16] [17] These molecules can trigger a range of pathogenic responses in the IVD cells that promote autophagy, senescence or apoptosis. 8, 18, 19 Secreted proinflam matory mediators associated with IVD degeneration include TNF, IL-1α, IL-1β, IL-6, IL-17, IL-8, IL-2, IL-4, IL-10, interferon-γ (IFN-γ), various chemokines and prostaglandin E 2 (PGE 2 ); [20] [21] [22] [23] [24] of these, TNF and IL-1β are probably the most studied. TNF has been implicated in disc herniation and nerve irritation and ingrowth, 25, 26 and both TNF and IL-1β induce upregulation of genes encoding ECM-degrading enzymes. 20, 27, 28 Furthermore, increased expression of IL-1β and IL-1 receptor (IL-1R) has been demonstrated in degenerated IVD tissue. 20, 21 In terms of promoting the degenerative response, marked increases in the expression of matrix metalloproteinase (MMP)-1, MMP-3, MMP-7, MMP-9, MMP-13, a disintegrin and metalloprotease with thrombo spondin motifs (ADAMTS)-1, ADAMTS-4, ADAMTS-5, ADAMTS-9 and ADAMTS-15 have been noted in the NP during degeneration, and their presence has raised fundamental questions concerning the regulation of these proteolytic enzymes during the disease process. 29, 30 IVD degeneration might begin with the aforementioned molecular changes within the NP or the AF (or both), although the subsequent progression of degeneration involves inflammatory changes in the discal and surrounding tissues. 23, 31, 32 Structural deficits in the NP and AF, and the formation of tears and clefts in these IVD tissues, as well as disc herniation in some instances, Key points ■ Intervertebral disc (IVD) degeneration is a common condition, affecting a large percentage of the adult population, with huge socio-economic costs ■ IVD disease is frequently associated with back, neck and radicular pain ■ Inflammatory cytokines play a major part in the pathogenesis of IVD degeneration by promoting extracellular matrix breakdown and recruitment of immune cells to the discal tissues ■ Infiltration and activation of immune cells in the IVD results in amplification of the inflammatory responses and the release of neurotrophins ■ Inflammatory cytokines and neurotrophins promote the generation of pain through changes in nociceptive neuron ion channel activity, as well as apoptosis of these cells in the dorsal root ganglion ■ An enhanced understanding of the contribution of cytokines and immune cells to IVD degeneration, inflammation and nociception could enable the identification of novel potential therapeutic targets in symptomatic IVD disease could enable immune cell activation and infiltration. This hypothesis is supported by the results from studies that showed the infiltration of CD68 + macrophages, neutrophils and T cells (CD4  + and CD8   +   ) , along with the invading blood vessels, in herniated discs. 23, 31 Of note, the migration of immune cells into the IVD is also accompanied by the appearance of nociceptive nerve fibres, which originate from the dorsal root ganglion (DRG), within the disc tissues. [33] [34] [35] Concomitantly, NP cells and the infiltrating immune cells continue to release cytokines as well as neurogenic factors, such as β-nerve growth factor (β-NGF) and brain-derived neurotrophic factor (BDNF). In the DRG, these neurotrophins induce expression of neuronal pain-associated cation channels, in particular, acid-sensing ion channel 3 (ASIC3) and transient receptor potential cation channel subfamily V member 1 (TRPV1). [36] [37] [38] In the context of the inflammatory milieu within the discal tissues, depolarization of these nociceptor ion channels would be expected to promote discogenic pain and reinforce cytokine-mediated IVD degeneration. Thus, this pathogenic cascade can explain the relationship between IVD degeneration and low back pain.
TNF and IL-1 in IVD degeneration
Overview of TNF signalling TNF is a cytokine that has been strongly linked to the pathogenesis of IVD degeneration. 21, 22, 24 The secreted form of this cytokine is generated via a disintegrin and metalloproteinase domain containing protein 17 (ADAM-17; also known as TNF-α-converting enzyme [TACE])-mediated proteolytic cleavage of a stable homotrimeric complex of type II transmembrane proteins. 39 The membrane-bound and secreted forms of TNF have both overlapping and distinct biological activities. Two cognate homotrimeric receptors exist for TNF in humans: TNF receptor 1 (TNFR1; also known as TNF receptor superfamily member 1A), which has both proapoptotic and antiapoptic functions; and TNF receptor 2 (TNFR2; also known as TNF receptor super family member 1B), which lacks the death domains found on the intracellular regions of TNFR1 and is primarily involved in antiapoptotic signalling. 40 Like the membrane-bound form of TNF, the extracellular domains of both TNFR1 and TNFR2 are also subject to proteolytic cleavage, which generates soluble forms of these receptors that bind TNF with high affinity and serve as antagonists of TNF signalling. Whereas both membrane-bound and soluble TNF signal through the ubiquitously expressed TNFR1, only the membrane-bound form of TNF signals via TNFR2, a receptor that is restricted to haematopoietic and immune cells. 40 Upon ligand binding, TNFR1 is able to form two distinct signalling complexes: the antiapoptotic complex I and the pro-death complex II, also known as the deathinducing signalling complex (DISC). With regard to the formation of complex I, conformational change results in dissociation of an inhibitory protein, silencer of death domains (SODD; also known as BAG family molecular chaperone regulator 4) from the intra cellular death domain of the receptor. 40, 41 This dissociation permits the recruitment of an adaptor protein, TNFR1-associated death domain protein (TRADD), which serves as a docking site for accessory proteins of the receptor complex, including TNF-receptor-associated factor 2 (TRAF2) and receptor-interacting serine/threonineprotein kinase 1 (RIP1). 40, 41 Signalling downstream of complex I is mediated by nuclear factor κB (NFκB) and mitogen-activated protein kinase (MAPK) pathways. Complex II can form after internalization of TNFR1 complex I and mediates the relatively minor role of TNFR1 in promoting cell death. 40, 41 On the other hand, whereas TNFR2 is predominantly anti apoptotic, data now suggest that TNFR2 can promote TRAF2 degradation. 40, 41 This pathway might represent an autoregulatory mechanism for controlling the activity of TNFR2, while at the same time modifying TNFR1 function to block antiapoptotic effects. 40, 41 Overview of IL-1α and IL-1β signalling Another cytokine that has been closely linked to disc degeneration is IL-1. 20, 21 The IL-1 family consists of 11 cytokines, of which IL-1α and IL-1β are the most studied. Similar to TNF, all of the members of the IL-1 family, except IL-1 receptor antagonist (IL-1Ra), are synthesized as precursor proteins and subsequently processed to shorter active peptides via proteolytic cleavage. These proteins belong to the leaderless secretory protein group, displaying no prototypic signal peptide required for processing, and thus their secretion bypasses the endoplasmic reticulum and Golgi apparatus. 42, 43 Interestingly, pro-IL-1β is biologically inactive, does not engage IL-1 receptor type 1 (IL-1R1) and requires proteolytic processing by either the intracellular cysteine protease caspase-1 or extracellular neutrophil proteases, whereas the membrane-associated IL-1α propeptide can signal through its cognate receptor to initiate cell-to-cell signalling. 42, 43 Moreover, unlike IL-1β, IL-1α is a dual-function cytokine; its biological functions are elicited through IL-1RI-mediated signalling as well as via nuclear translocation of pro-IL-1α or a 16 kDa N-terminal propeptide cleavage product (ppIL-1α), which act as transcription factors, independent of binding to cell surface receptors ( Figure 2) . 42, 43 Similarly to TNF, IL-1α and IL-1β can ac tivate NFκB and MAPK signalling pathways.
Association of IL-1 and TNF with IVD disease Both IL-1 and TNF are produced by cells of the IVD, [20] [21] [22] as well those of the immune system (macrophages, monocytes, dendritic cells, B cells and natural killer cells). These cytokines have a number of common functions, which include chemoattraction of neutrophils, induction of adhesion molecule expression on endothelial cells, stimulation of phagocytosis, and production of PGE 2 by macrophages. [42] [43] Increased levels of IL-1 and TNF, along with other inflammatory mediators, have been observed in degenerate and herniated inter vertebral discs 20, 21 and in the epidural space. 24 Furthermore, Le Maitre et al. 20 showed that IVD cells from both nondegenerate and degenerate tissues produced IL-1, IL-1Ra, IL-1R1 and caspase-1, and that expression of these proteins, with the exception of IL-1Ra, increased with severity of disease. In a follow-up study, 21 these researchers demonstrated that degenerate and herniated discs exhibit increased expression of both TNF and IL-1β compared with nondegenerate IVD tissue, with IL-1β expressed at higher levels and in a larger proportion of the samples than TNF. Likewise, a 10-fold elevation in IL1R1 mRNA expression was found in degenerate discs compared with nondegenerate disc tissue, and 80% of degenerate disc cells displayed IL-1R immuno positivity compared with 30% of cells from nondegenerate discs. 21 However, no increase in the expression of the gene encoding TNFR1 or TNFR1 protein expression was observed in degenerate or herniated discs. 21 The authors concluded that, although both cytokines might be involved in the pathogenesis of disc disease, IL-1 might have a more prominent role than TNF, and thus would serve as a better target for therapeutic intervention. 21 In 2013, Kepler et al. 17 reported that human IVD cells treated with IL-1β or TNF upregulated the expression of substance P; this neuropeptide also induced expression of IL-1β, IL-6 and IL-8 in both NP cells and AF cells. In a separate study, 44 these investigators reported that IL-1β and CC chemokine ligand 5 (CCL5; also known as RANTES) were expressed at substantially higher levels in painful discs than in nonpainful discs, and that expression of these factors increased with increasing grade of IVD degeneration. Another 2013 study demonstrated that Il1rn-null mice, which lack the negative regulator of IL-1 signalling IL-1Ra, were susceptible to IVD degeneration, further validating the importance of IL-1 and IL-1Ra in the pathogenesis of disc disease. 45 Nonetheless, in contrast to the earlier findings of Le Maitre and colleagues, 21 Andrade et al. 46 reported an increased expression of both TNFR1 and TNFR2 in herniated NP and AF tissue compared with tissue from patients with scolio sis who served as controls in this study. A positive correlation was demonstrated between both TNF and TNFR1 protein expression in NP tissue and pain assessed using the visual analogue scale (VAS), although no correlation between TNFR2 levels in NP tissue and VAS score was noted. Interestingly, a negative correlation between TNFR2 levels in the AF and VAS score was observed, suggesting a more complex interaction than has been hitherto described. 46 Thus, IL-1β and TNF are the key inflammatory cytokines involved the patho genesis of IVD degeneration, disc herniation and discogenic pain. Several organ culture models of IVD degeneration support this concept.
18,47
Contributions of TNF and IL-1 to IVD disease Cytokine production by IVD cells was found to be responsive to various environmental stressors including smoking, abnormal mechanical loading, injury and infection. [48] [49] [50] [51] The cytokines released have been shown to upregulate chemokines and a variety of catabolic me diatorsincluding ADAMTS-4, ADAMTS-5, MMP-1, MMP-2, MMP-3, MMP-13 and MMP-14-and to suppress the expression of important ECM genes.
20,22,27,52
Mediators of structural change With regard to the regulation of catabolic enzymes, Seguin et al. 53 demonstrated that TNF induced MMP-2 activity post-translationally (that is, without altering MMP-2 gene or protein expression) in bovine NP tissue, seemingly by increasing MMP-14 expression via the extracellular signal-regulated kinase (ERK) MAPK signalling pathway. Of potential relevance to IVD disease, syndecan-4, a key heparan sulphate proteo glycan involved in the activation of many growth factors and MMPs, was found to be required for TNF-dependent or IL-1β-dependent activation of ADAMTS-5 in rat NP cells; 27 syndecan-4 expression was dependent on NFκB activity. 27 Interestingly, syndecan-4 was found to promote ADAMTS-5 processing and thus indirectly regu late aggrecan turnover. 27 Furthermore, increased TNF, IL-1β, syndecan-4 and ADAMTS-5 expression, and concomitant increases in aggrecan degradation were associated with IVD degeneration in human tissues. 27 Unlike in chondrocytes, 54 syndecan-4-dependent ADAMTS-5 processing in NP cells was independent of MMP-3 activity. 27 In addition to mediating the post-translational processing and activity of ADAMTS-5, we and others have demonstrated that TNF and IL-1β also regulate the expression of ADAMTS-5, as well as ADAMTS-4, through MAPK and NFκB signalling pathways. 53, 55 Concerning the role of these proteases in IVD disease, both ADAMTS-4 and ADAMTS-5 protein levels increase in disease, 27 ,56 although only ADAMTS-4 levels were Figure 2 | IL-1α and IL-1β synthesis and signal transduction pathway. IL-1α and IL-1β are synthesized as precursor proteins (pro-IL-1α and pro-IL-1β), which then undergo proteolytic cleavage by calpain and caspase-1, respectively, to produce the mature active forms. Although pro-IL-1β is biologically inactive, myristoylated membrane-associated pro-IL-1α can signal through IL-1R on adjacent cells to initiate cell-to-cell signalling. In addition, nuclear translocation of pro-IL-1α or the cleaved N-terminal pro-peptide that retains its NLS elicits biological functions. Pro-IL-1α, IL-1α and IL-1β can all bind to IL-1R1, which enables recruitment of the IL-1RAcP co-receptor. A cascade of events downstream of the IL-1R complex results in the activation of important signalling proteins, such as mitogen-activated kinases (JNK, p38, ERK1/2), as well as transcription factors, including NFκB (p65 and p50 subunits) and c-Jun (a subunit of AP-1), which control expression of a number of inflammatory and catabolic genes. Signalling through the IL-1R complex is modulated by inhibitory actions of IL-1R2, sIL-1R2, sIL-1RAcP and IL-1Ra. Abbreviations: AP-1, activator protein 1; ERK1/2, extracellular signal-regulated kinase 1/2; IκB, inhibitor of nuclear factor κB; IKK, IκB kinase; IL-1R1, IL-1 receptor 1; IL-1R2, IL-1 receptor 2; IL-1Ra, IL-1 receptor antagonist; IL-1RAcP, IL-1 receptor accessory protein; IRAK, IL-1 receptor-activated protein kinase; JNK, c-Jun N-terminal kinase; MyD88, myeloid differentiation primary response gene 88; NFκB, nuclear factor κB; NLS, nuclear localization sequence; sIL-1R2, soluble IL-1R2; sIL-1RAcP, soluble IL-1RAcP; TAK1, transforming-growth-factor-β-activated protein kinase 1; TRAF6, TNF receptor-associated factor 6.
corre lated with disease severity. 56 Nonetheless, silencing of ADAMTS5 alone was sufficient to block aggrecan degrada tion, reflected in considerable improvements in MRI and histological scores compared with control animals, in a rabbit annular needle-puncture model of IVD degeneration. 57 Lending support to these findings, we subsequently found that silencing of either ADAMTS4 or ADAMTS5 in human NP cells resulted in the inhibition of TNF-induced aggrecan neoepitope generation, a marker of aggrecan degradation. 53 Therefore, that ADAMTS-4 and ADAMTS-5 are non-redundant is a reasonable assumption, and thus therapeutic blockade of one, or both, of these proteases would be expected to limit breakdown of the aggrecan-rich ECM of the IVD and possibly mitigate structural changes.
Owing to the critical role NFκB has in mediating the effects of inflammatory cytokines, our group has investigated whether other regulatory molecules control the activity of this signalling pathway in NP cells. Our results suggest that, in the presence of inflammatory cytokines, Egl nine homologue 3 (EGLN3; a molecule with important roles in hypoxia inducible factor [HIF]-1α signalling 58 ) forms a regulatory circuit with NFκB, serving as a transcriptional co-activator; 59 TNF-NFκB-dependent induction of syndecan-4, ADAMTS-5, MMP-13 and cyclo-oxygenase-2 was decreased in EGLN3 loss-offunction studies. 59 Moreover, suppression of EGLN3 expression, but not its hydroxylase activity, prevents TNF-mediated inhibition of the expression of aggrecan and type II collagen encoding genes, 59 which are critical for the maintenance of the NP tissue matrix. Of note, whereas cytokines induced EGLN3 expression through NFκB, HIF-1α did not seem to be involved this process. 59 These findings clearly indicate that EGLN3 is a critical component of the cytokine transduction pathway in NP cells. This molecule is, as such, likely to have a critical role in the pathogenesis of degenerative IVD disease and represents a novel pharmacological target.
Regulators of immune cell recruitment
Aside from causing structural changes, inflammatory cytokines stimulate IVD cells to produce chemotactic factors, which promote the recruitment of macrophages, neutrophils and T cells. Analysis of degenerate and herniated IVD tissues has demonstrated elevated levels of several chemokines including CCL2, CCL3, CCL4, CCL5, CCL7, CCL13, CXC chemokine ligand 10 (CXCL10) and IL-8. 44, [60] [61] [62] Moreover, treatment of cultured IVD cells with TNF and IL-1β, in vitro, causes an increase in the production of many of these chemokines; 17, 44, 61 NP cells have been shown to express both CCL3 and CCL4, and their expression is regulated by TNF and IL-1β. 61 In concert with other cytokine-responsive catabolic genes, CCL3 expression is controlled through MAPK and p65-dependent NFκB signalling pathways. 61 In contrast to the p65 NFκB subunit, the NFκB p50 subunit is inhibitory to CCL3 expression. 61 Through induction of CCL3 expression by NP cells, inflammatory cytokines promote CC chemokine receptor type 1 (CCR1)-dependent macrophage migration. 61 Importantly, analysis of human tissues has revealed that the extent of CCL3 expression correlates positively with the grade of IVD degeneration and that expression levels are higher in herniated disc tissue compared with degenerate but contained discs. 49 Thus, macrophage infiltration into the disc, and the associated inflammatory and pain response, would probably be limited if CCR3-CCL1 signalling could be blocked. In addition, IVD cells co-cultured with macrophages have increased expression of IL-8, another potent chemotactic factor, along with TNF, IL-6 and PGE 2 . 63 Furthermore, co-neutralization of IL-8 and TNF markedly improved the symptoms of mechanical hyperalgesia in both disc autograft and spinal nerve ligation models. 63 These findings all point to a central role for inflammatory cytokines and chemotactic factors in the recruitment of immune cells to the IVD and associated tissues, which are critical steps in the pain generation pathway.
Effects on IVD cell homeostasis
In addition to the catabolic and proinflammatory effects we have discussed, IL-1β and TNF have been shown to influence IVD cell senescence, 18 autophagy, 19 and expression of genes involved in regulation of cell proliferation and renewal. 64 Genes of the Notch pathway, which regulates cell proliferation, 64 differentiation and fate determination, are upregulated by these cytokines in NP cells via signalling dependent on NFκB and MAPK. 65 In terms of potential clinical relevance of this finding, in human tissues, expression levels of NOTCH2, IL-1β and TNF are raised in histologically midgrade degenerate discs compared with nondegenerate discs. 65 Similarly, a strong corre lation between the expression of NOTCH2, NOTCH1 and the Notch target gene HEY2 has also been noted. 65 These results provide insight into the mechanistic link between the high levels of inflammatory cytokines and the dysregulated expression of genes of the Notch signalling pathway observed during IVD disease, 64 and suggest that the inflammatory milieu can alter IVD cell renewal and differentiation-processes that are important for tissue repair and homeostasis.
Contribution of IL-6 to IVD disease IL-6 is a cytokine that signals through a type I cytokine receptor complex comprising the ligand-binding IL-6 receptor subunit α (IL-6Rα; also known as CD126) and the signal-transducing component gp130 (also known as CD130).
66 gp130 is ubiquitously expressed and mediates signalling by several IL-6 family members, including ciliary neurotropic factor, leukaemia inhibitory factor, IL-11, cardiotrophin-1 and oncostatin M; by contrast, IL-6Rα expression is tissue restricted. A soluble form of IL-6R (sIL-6R) can be generated either from an alternatively spliced IL6R mRNA or, more commonly, by proteolytic cleavage of membrane-bound IL-6Rα by ADAM-17. Complexes containing sIL-6R and IL-6 can bind gp130, induce dimerization and initiate signalling (known as trans-signalling) in cells that do not express IL-6Rα, thus serving as a paracrine factor. 66 Binding of IL-6 to the IL-6Rα-gp130 complex induces signalling primarily through Janus kinase (JAK)-signal transducer and activator of transcription (STAT), Ras and phosphoinositide 3-kinase (PI3K) pathways, 16 and has varied biological effects, from growth and differentiation of B cells and T cells to acute-phase protein expression.
Aside from T cells and macrophages, IL-6 is secreted by IVD cells, 16 and higher expression levels were found in herniated discs from patients with chronic sciatic pain than in samples from patients with painless scolio sis. 67 Studer et al. 68 showed that IL-6 together with sIL-6R potentiates the catabolic actions of IL-1 and TNF on NP cells from degenerated human discs; treatment of these cells with this cocktail of cytokines markedly decreases proteoglycan synthesis and is associated with robust increases in PGE 2 and MMP-13 levels. 68 In addition to its catabolic effects on NP cells, IL-6 induces TNF expression and apoptosis of neuronal cells in the DRG, 69, 70 events which might contribute to allodynia (pain resulting from a stimulus that would not usually provoke a pain response) and hyperalgesia. Such a role for both IL-6 and TNF in the generation of neuropathic pain was noted following transection of L5 ventral root. 71 Further support for the hypothesis that IL-6 contributes to sciatic pain comes from the observation that an IL6 haplotype (GGGA) comprising 4 single nucleotide polymorphisms (SNPs) in exon 5 was more common in patients with symptomatic IVD disease (sciatica) than in individuals without the disease. 72 A subsequent study by the same group using the additive inheritance model indicated that the disease risk was substantially increased in young adults carrying G alleles of the IL6 SNPs rs1800795 and rs1800797. 73 Moreover, haplotype analysis revealed an association between the GGG haplotype (SNPs rs1800797, rs1800796 and rs1800795) and IVD disease, 73 validating the importance of IL-6 in disease aetiology. However, the consequences of individual SNPs on IL-6 function in the context of the IVD remains to be elucidated. Together, these findings nonetheless indicate that targeting of IL-6 could have beneficial effects on both ECM degradation by NP cells, and importantly, nociception.
Roles of IL-17 and IFN-γ in IVD disease
IL-17A is the founding member of the IL-17 cytokine family, which comprises six proteins (IL-17A-F). The different IL-17 cytokines interact with various type I cell surface receptors of the IL-17R family, which consists of five broadly distributed receptors (IL-17RA-E) with individual ligand specificities. 74 For example, signal transduction by IL-17A requires the presence of a heterodimeric receptor complex consisting of both IL-17RA and IL-17RC. Signal transduction by these receptors is diverse and depends on the nature of the stimulus and target tissue; AP-1, TRAF6, NFκB, c-Jun N-terminal kinase (JNK), ERK1/2 and p38 have all been implicated in signalling downstream of IL-17-IL-17R complexes. 74 IL-17 family member signalling increases chemokine production and promotes the recruitment of monocytes and neutrophils to sites of inflammation. 74 Production of IL-17 cytokines has been shown to be induced by IL-23 and primarily in type 17 T-helper (T H 17) cells, as well as other lymphocytes and, more recently, in neutrophils, mast cells and even IVD cells. [74] [75] [76] Under many circumstances, IL-17 acts synergistically with TNF and IL-1 to enhance the inflammatory response. 74 IFN-γ is another important molecule that has been associated with IVD degeneration. 23 In humans, IFN-γ, the sole type II IFN, is secreted as a dimer that engages a heterodimeric receptor comprising IFN-γ receptor 1 and IFN-γ receptor 2 chains. 77 Similar to IL-6R, this receptor complex signals through the JAK-STAT pathway. IFN-γ has also been shown to interact with cell surface heparan sulphate molecules, which inhibit its biological activity. 78 The physiological relevance of this interaction is not well understood, although binding to heparan sulphate mol ecules might protect this cytokine from proteolysis. IFN-γ is secreted by type 1 T-helper (T H 1) cells, cytotoxic T (T C ) cells and natural killer cells, as well as macrophages, myeloid cells and dendritic cells. 77 Owing to its prominent role in inflammatory arthritis, considerable attention has been directed at IL-17 in rheumatic diseases. 76 Of relevance to IVD disease, Kim et al. 79 showed that IL-17 signalling has important roles in the recruitment of T cells and macrophages, as well as glial cell and astrocyte activation in the context of sciatic nerve injury and subsequent neuropathic pain. Furthermore, in IVD cells, IL-17 and IFN-γ cause a syner gistic increase in the release of inflammatory mediators, and an elevation in intercellular adhesion molecule 1 (ICAM-1) expression. 80 More recently, Shamji et al. 23 extended the earlier work of Park and co-workers, 81 demonstrating that levels of IL-4, IL-6 and IL-17, in addition to IFN-γ and IL-12, are increased in degenerated and, to a greater extent, herniated discs compared with nondegenerated autopsy control samples. Similarly, evaluation of the cytokines in IVD lavage samples revealed a considerable elevation in levels of IFN-γ in patients experiencing low back pain compared with individuals with scoliosis. 82 The presence of these cytokines in degenerated IVD samples implies that infiltration of leukocytes into the discal tissues has occurred. In support of this idea, Shamji and colleagues 23 found a markedly higher infiltration of CD68 + macrophages, and a trend towards increased CD4 + T-cell infiltration in herniated discs, compared with nondegenerated control tissue. Furthermore, as IL-17 is secreted by T H 17 cells, these cells probably have an important part in IVD degeneration. However, the prominent IL-17 staining of nondegenerate control tissues observed in the study by Shamji et al. 23 raises the possibility that other cell types, including resident IVD cells, could contribute to the production of this cytokine. A 2013 publication by Gruber et al. 75 supports this theory, revealing that IVD cells can produce IL-17 when stimulated using TNF and IL-1β and that IL-17 expression increased with the degree of IVD degeneration.
The fact that Shamji et al. 23 showed that IL-12 and IFN-γ levels are elevated, as well as identifying the trend towards increased CD4 + T-cell infiltration in herniated tissues, indicates that a contribution from T H 1 cells to IVD degeneration is also probable. Moreover, the presence of increased levels of IL-4 also suggests involvement of CD4 + type 2 T-helper (T H 2) cells in the degenerative process. 23 Interestingly, these local inflammatory changes are reflected at the systemic level; 83 in patients with lumbar disc herniation substantial increases in CD4 + , CD8 + and CD3 + lymphocyte populations, as well as the CD4 + :CD8 + cell ratio in the peripheral circulation, have been reported compared with those observed in healthy individuals. 83 Moreover, a positive correlation was observed between VAS pain scores and numbers of CD4 + T cells and the CD4 + :CD8 + T cell ratio. 83 The relationship between type of IVD herniation, pain and T-cell response in the peripheral circulation has also been investigated. 84 The results from this study indicated that CD3 + cell and CD4 + cell populations are increased in the ruptured IVD herniation group compared with the degenerated disc herniation group. In addition, a positive correlation was observed between CD4 + T cell numbers and the CD4 + :CD8 + cell ratio, and pain measured by the positive straight leg raise test. 84 Figure 3 depicts the contribution of various immune cells to the pathogenesis of IVD disease.
Cytokines and IVD-associated pain
The onset of discogenic pain is characterized by nerve fibre ingrowth into an otherwise aneural IVD; [33] [34] [35] the interplay between inflammatory cytokines and neurotrophins produced by disc cells and infiltrating immunocytes, and neuronal neurotrophin receptors and their modulators, might guide this process. In the healthy state, nerve fibre ingrowth into the IVD is prevented by the high concentration of the chondroitin sulphate presented by aggrecan and other ECM molecules, which is inhibitory to nerve outgrowth. 85 Thus, during IVD degeneration, an increase in keratan sulphate:chondroitin sulphate ratio and proteolytic cleavage of aggrecan mediated by cytokine-dependent ADAMTS-4 and/or ADAMTS-5 activity could enhance nerve invasion. 27, 52 In addition, semaphorin-3A, which is known to be inhibitory to axonal growth, is highly expressed in the outer AF in healthy IVD tissue. 86 Interestingly, expression of semaphorin-3A was found to decrease with increasing grades of IVD degeneration in patients with discogenic pain, and tissues with low levels of this protein had increased expression of markers of neurovascular ingrowth. 86 These data suggest that semaphorin-3A might inhibit nerve ingrowth into the IVD.
Indeed, Freemont et al. 35 observed a direct relationship between nerve fibre ingrowth and the presence of blood microvessels in painful discs, and suggested that β-NGF derived from endothelial cells lining the IVD neovasculature is required for neuronal survival and ingrowth. However, both NP cells and AF cells express low levels of β-NGF and BDNF and the neurotrophin receptors tropomyosin-related kinase A (Trk-A), Trk-B and p75 NTR (also known as TNF receptor superfamily member 16). 87, 88 Moreover, neurotrophin expression is increased in painful and degenerate discs and is sensitive to IL-1β and TNF. [89] [90] Accordingly, not only could IVD cell-derived β-NGF participate in nerve ingrowth, but this neurotrophin might also directly act on nerve cells in the DRG to promote expression of ASIC3, a pH-sensitive Na + channel associated with ischaemic and inflammatory pain. 36, 87 In concert, cytokines can also act on the DRG, promoting apoptosis of nerve cells, 67, 68 as well as the upregulation of TrpV1 nociceptive cation channel expression. 91, 92 Of note, nerve fibres that innervate IVD tissues are categorized as nociceptive and are thought to be derived from the DRG: they express acetyl cholinesterase, ubiquitin carboxyl-terminal hydrolase isozyme L1 (also known as PGP9.5), substance P, BDNF, TrpV1, calcitonin-gene-related peptide (CGRP) and neurofilament polypeptides. [92] [93] [94] [95] [96] These relationships suggest a direct linkage between inflammatory cytokines, neurotrophins and nociception (Figure 4) .
Evidence from clinical studies
Evidently, inflammatory cytokines have a major role in all aspects of degenerative IVD disease, including pain generation. Table 1 lists studies that have investigated the potential for anticytokine agents and signalling pathway inhibitors to ameliorate structural damage and mitigate neuropathic pain in cell or organ culture models, or animal models. By contrast, human clinical trials are solely directed at alleviating the symptoms of back or radicular pain associated with IVD degeneration, disc herniation and spinal stenosis. To date, the results of such trials have been mixed (Table 2) .
In patients experiencing radicular pain owing to lumbar spinal stenosis, epidural application of TNF inhibitor etanercept, 97 a TNF receptor IgG fusion protein, or the IL-6 inhibitor tocilizumab, 98 an anti-IL-6R monoclonal antibody, to the spinal nerve produced pain relief. At 1-month follow-up, patients exhibited substantial improvements in low back pain, leg pain and leg numbness. 97, 98 In a randomized, double-blinded, placebocontrolled trial, Genevay et al. 99, 100 studied the efficacy of two subcutaneous injections of adalimumab, a fully human antibody targeting TNF, on severe acute sciatica. The results from short-term 99 and 3-year follow-up 100 studies clearly showed a marked improvement in leg pain and a reduction in the number of patients requiring back surgery in the adalimumab-treated group compared with the control cohort. A 6-week pilot controlled group study 101 in patients with severe sciatica found that, compared with a control group treated with intravenous TNF, IL-1β, IL-6 Nerve ingrowth
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Figure 4 | Schematic of major interdependent and overlapping phases leading to IVD degeneration and pain. Following initial insult, IVD cells upregulate expression of inflammatory cytokines and chemokines, including TNF, IL-1β and IL-6, as well as IL-17 and CC motif chemokines. In this inflammatory environment, IVD cells express several catabolic molecules such as syndecan-4, ADAMTS-4/5 and MMPs. These enzymes promote degradation of predominant extracellular matrix molecules such as aggrecan and collagen II. Continuous structural breakdown of matrix molecules of the NP and AF results in mechanical instability, annular tears and in many instances disc herniation. In the second phase of the disease, release of chemokines and cytokines from the degenerated IVD enhances activation and infiltration of leukocytes into tissues, further amplifying the inflammatory response. Infiltration of immune cells is accompanied by neovascularization and the appearance of nociceptive nerve fibres that arise from the DRG in the IVD. In the third phase of the disease, neurogenic factors, in particular β-NGF and BDNF, produced by the herniated disc and invading leukocytes induce expression of painassociated cation channels such as ASIC3 and TrpV1 in the DRG. In this inflammatory milieu, activation of these channels is likely to promote discogenic pain and reinforce cytokine-mediated IVD degeneration. Possible sites of targeted pharmacological intervention are indicated by red inhibitory lines. Abbreviations: ADAMTS-4/5, a disintegrin and metalloproteinase with thrombospondin motifs 4/5; AF, annulus fibrosus; ASIC3, acid-sensing ion channel 3; BDNF, brainderived neurotrophic factor; β-NGF, β-nerve growth factor; DRG, dorsal root ganglion; IVD, intervertebral disc; IFN-γ, interferon-γ; MMPs, matrix metalloproteinases; NP, nucleus pulposus; SDC4, Syndecan-4; TrpV1, transient receptor potential cation channel subfamily V member 1. 102 demonstrated considerable improvements in leg and back pain in a small cohort of patients with sciatica who were treated with epidural injections of etanercept in a randomized, double-blinded placebocontrolled trial. However, a small randomized controlled trial (n = 15) found a trend towards no benefit of epidural etanercept over placebo. 103 These data are in keeping with the results of a subsequent trial, in which epidural etanercept was also found to be less efficacious than epidural steroids with respect to leg pain, back pain and functional capacity in patients with lumbosacral radiculopathy. 104 Similarly, no statistically significant differences in lumbar radicular pain outcomes were seen after 1-year follow-up in a trial of infliximab, a mouse-human chimeric anti-TNF antibody, although a beneficial effect was noted for patients with L3-L4 or L4-L5 IVD herniation with colocalized MRI-detected pathological Modic changes in the vertebrae. 105 The discrepancy in the outcomes of these studies could be the result of technical and study design issues, such as problems with controlled delivery required to maintain the optimum therapeutic dose, inherent differences in the investigational molecules, limited cohort size and the issue of patient selection, rather than a reflection of the actual importance of cytokines in the degenerative process. Thus, larger and better designed studies are now required to investigate these therapies in patients with IVD disease. Importantly, in addition to functional outcome measures, the use of more sensitive imaging technologies is necessary to detect tissue structural changes that might occur following the anticytokine biologic therapy.
Conclusions
IVD degeneration is characterized by three distinct but overlapping phases, in which cytokines have a central role (Figure 4 ). In the first phase, an initiating event results in phenotypic changes in the IVD and the production of cytokines and chemokines by both NP cells and AF cells. During the second phase, further amplification of the inflammatory response occurs as a result of infiltration of the IVD by leukocytes, as well as neovascularization and nerve ingrowth into the structurally deficient discal tissues. In the final stage, sensitization of nerve endings and the modulation of DRG pain channel activity by inflammatory mediators and neurotrophins results in pain. Cytokines have a major role in each of these three stages although, after injury, cytokines might be critically important for the repair and regeneration of peripheral nerves. Nadeau et al. 106 demonstrated that, whereas mice lacking both IL-1β and TNF, or both IL-1R1 and TNFR1, exhibited decreased nociception and recruitment of neutrophils and M1 macrophages following sciatic nerve injury, recovery of nerve function and axonal regeneration was also impaired, independent of neutrophil recruitment. These interesting results suggest that targeting specific IL-1β-dependent and/or TNF-dependent responses, such as neutrophil and macro phage recruitment, that might be responsible for nociception could be a better therapeutic strategy for patients experiencing radicular pain associated with nerve root injury following disc herniation than complete blockage of cytokine production. Furthermore, as cytokines form a complex regulatory network, the assumption that targeting the actions of a single cytokine might have a limited clinical effect is not unreasonable. What is now required is a therapy that simultaneously targets specific actions of multiple key cytokines (Figure 4 ). An enhanced understanding of the contribution of cytokines and immune cells to the structural degeneration of the discal tissues, inflammation and pain could lead to the identification of novel therapeutic targets and enable the effective treatment of symptomatic IVD disease without interfering with the tissue repair programme.
Review criteria
PubMed was searched for full-text, English-language original and review articles published between 1997 and 2013. The search terms used, either alone or in various combinations, were: "intervertebral disc"; "intervertebral disc degeneration"; "back pain"; "sciatic pain"; "TNF"; "IL-1"; "IL-17"; "IL-6"; "IFN-γ"; "inflammatory cytokines"; "chemokines"; and "neurotrophins". The reference lists of identified articles were searched for further relevant papers.
